Secondary Infusion of Relma-cel Injection for Relapsed or Refractory B-cell Lymphoma

Patients who have undergone at least one disease assessment after initial Relma-cel treatment and have not achieved complete remission may receive a second treatment based on clinical practice. The specific dosage will be determined by the investigator according to the patient's condition and available dose reserves.